PAREXEL International launches Perceptive MyTrials Data-Driven Monitoring solution

PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced the launch of its Perceptive MyTrials® Data-Driven Monitoring solution. Developed by PAREXEL Informatics, it is a key component of the Perceptive MyTrials eClinical platform, an integrated suite of applications for managing clinical trials. 

On-site monitoring is a critical aspect of trial management, with the primary function of identifying and mitigating patient safety or data quality risks at investigative sites. The U.S. Food and Drug Administration (FDA) and other regulatory bodies have issued guidance to assist sponsors in developing risk-based monitoring strategies that enhance patient protection and improve trial data quality through more effective study oversight. They have encouraged greater use of centralized monitoring methods to evaluate clinical trial conduct and progress.

PAREXEL's new data-driven monitoring solution provides an innovative approach to centralized risk-based monitoring. The technology captures, consolidates and organizes clinical information in real-time from disparate sources. As a result, drug developers can accurately identify study risks and rapidly determine what type of intervention may be required. Monitoring focused on specific risk offers the potential to enhance patient safety, reduce costs and promote regulatory compliance.  

"Perceptive MyTrials Data-Driven Monitoring uses clinical data to guide monitoring activities as an alternative to periodically scheduled monitoring visits, which can be time-consuming, costly and inefficient," said Xavier Flinois, President of PAREXEL Informatics. "Greater insight into study data allows for a more precise determination of when on-site monitoring visits need to occur and what activities should be undertaken during those visits. This can make clinical trial participation safer for patients while offering cost efficiencies for sponsors."

"Our data-driven monitoring solution builds on PAREXEL's long-standing track record of developing innovative technologies to continuously improve clinical processes," said Mark A. Goldberg, M.D., President and Chief Operating Officer, PAREXEL. "Perceptive MyTrials Data-Driven Monitoring represents the latest example of our leadership in bringing efficiencies to the drug development process."

Source:

PAREXEL International Corporation

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Parexel. (2019, June 19). PAREXEL International launches Perceptive MyTrials Data-Driven Monitoring solution. News-Medical. Retrieved on October 27, 2021 from https://www.news-medical.net/news/20140520/PAREXEL-International-launches-Perceptive-MyTrials-Data-Driven-Monitoring-solution.aspx.

  • MLA

    Parexel. "PAREXEL International launches Perceptive MyTrials Data-Driven Monitoring solution". News-Medical. 27 October 2021. <https://www.news-medical.net/news/20140520/PAREXEL-International-launches-Perceptive-MyTrials-Data-Driven-Monitoring-solution.aspx>.

  • Chicago

    Parexel. "PAREXEL International launches Perceptive MyTrials Data-Driven Monitoring solution". News-Medical. https://www.news-medical.net/news/20140520/PAREXEL-International-launches-Perceptive-MyTrials-Data-Driven-Monitoring-solution.aspx. (accessed October 27, 2021).

  • Harvard

    Parexel. 2019. PAREXEL International launches Perceptive MyTrials Data-Driven Monitoring solution. News-Medical, viewed 27 October 2021, https://www.news-medical.net/news/20140520/PAREXEL-International-launches-Perceptive-MyTrials-Data-Driven-Monitoring-solution.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
PAREXEL launches new China Advisory Service to help global biopharmaceutical companies navigate market opportunity within China